CN103710466B - 一种hbv的ymdd荧光pcr检测试剂盒 - Google Patents
一种hbv的ymdd荧光pcr检测试剂盒 Download PDFInfo
- Publication number
- CN103710466B CN103710466B CN201310744594.2A CN201310744594A CN103710466B CN 103710466 B CN103710466 B CN 103710466B CN 201310744594 A CN201310744594 A CN 201310744594A CN 103710466 B CN103710466 B CN 103710466B
- Authority
- CN
- China
- Prior art keywords
- hbv
- ymdd
- probe
- yvdd
- yidd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 36
- 241000700721 Hepatitis B virus Species 0.000 title abstract description 62
- 238000003752 polymerase chain reaction Methods 0.000 title abstract 7
- 229940009098 aspartate Drugs 0.000 title abstract 2
- 239000000523 sample Substances 0.000 claims abstract description 71
- 239000011324 bead Substances 0.000 claims abstract description 19
- 230000005291 magnetic effect Effects 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 42
- 238000007400 DNA extraction Methods 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 24
- 230000008859 change Effects 0.000 claims description 23
- 238000011144 upstream manufacturing Methods 0.000 claims description 23
- 239000013642 negative control Substances 0.000 claims description 15
- 239000013641 positive control Substances 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 235000011178 triphosphate Nutrition 0.000 claims description 7
- 239000001226 triphosphate Substances 0.000 claims description 7
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 7
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 7
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 6
- 239000005549 deoxyribonucleoside Substances 0.000 claims description 5
- 239000011535 reaction buffer Substances 0.000 claims description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims description 3
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 abstract description 25
- 238000000034 method Methods 0.000 abstract description 20
- 239000007788 liquid Substances 0.000 abstract description 15
- 238000000605 extraction Methods 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 230000035772 mutation Effects 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 229960000310 isoleucine Drugs 0.000 abstract description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract description 2
- 102000053602 DNA Human genes 0.000 abstract 3
- 239000012295 chemical reaction liquid Substances 0.000 abstract 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 17
- 230000003321 amplification Effects 0.000 description 16
- 238000003199 nucleic acid amplification method Methods 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 208000002672 hepatitis B Diseases 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000012925 reference material Substances 0.000 description 5
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001917 fluorescence detection Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
- 229960001627 lamivudine Drugs 0.000 description 4
- 125000006853 reporter group Chemical group 0.000 description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 108091036055 CccDNA Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical group C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310744594.2A CN103710466B (zh) | 2013-12-30 | 2013-12-30 | 一种hbv的ymdd荧光pcr检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310744594.2A CN103710466B (zh) | 2013-12-30 | 2013-12-30 | 一种hbv的ymdd荧光pcr检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103710466A CN103710466A (zh) | 2014-04-09 |
CN103710466B true CN103710466B (zh) | 2015-04-08 |
Family
ID=50403816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310744594.2A Active CN103710466B (zh) | 2013-12-30 | 2013-12-30 | 一种hbv的ymdd荧光pcr检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103710466B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105603122A (zh) * | 2016-01-22 | 2016-05-25 | 上海同科生物科技有限公司 | 一种乙型肝炎病毒ymdd基因突变检测试剂盒 |
CN110656204A (zh) * | 2019-11-14 | 2020-01-07 | 郑州安图生物工程股份有限公司 | 一种乙型肝炎病毒ymdd基因突变检测试剂盒及检测方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1710098A (zh) * | 2004-06-16 | 2005-12-21 | 上海复星医学科技发展有限公司 | 一种检测拉米夫定耐药hbv dna的方法及试剂盒 |
CN1737164A (zh) * | 2004-08-27 | 2006-02-22 | 上海复旦悦达生物技术有限公司 | 一种快速检测乙型肝炎病毒耐药基因变异的方法 |
CN101701267A (zh) * | 2009-11-26 | 2010-05-05 | 戴立忠 | 乙型肝炎病毒荧光定量pcr检测试剂盒及其应用 |
CN102796828A (zh) * | 2007-10-30 | 2012-11-28 | 株式会社东芝 | 用于检测乙型肝炎病毒的抗药性株系的核酸引物组、测定试剂盒及检测乙型肝炎病毒的抗药性株系的方法 |
-
2013
- 2013-12-30 CN CN201310744594.2A patent/CN103710466B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1710098A (zh) * | 2004-06-16 | 2005-12-21 | 上海复星医学科技发展有限公司 | 一种检测拉米夫定耐药hbv dna的方法及试剂盒 |
CN1737164A (zh) * | 2004-08-27 | 2006-02-22 | 上海复旦悦达生物技术有限公司 | 一种快速检测乙型肝炎病毒耐药基因变异的方法 |
CN102796828A (zh) * | 2007-10-30 | 2012-11-28 | 株式会社东芝 | 用于检测乙型肝炎病毒的抗药性株系的核酸引物组、测定试剂盒及检测乙型肝炎病毒的抗药性株系的方法 |
CN101701267A (zh) * | 2009-11-26 | 2010-05-05 | 戴立忠 | 乙型肝炎病毒荧光定量pcr检测试剂盒及其应用 |
Non-Patent Citations (2)
Title |
---|
Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan PCR;Sebastian Malmstrom等;《Journal of Virological Methods》;20070409;第143卷;第147-152页 * |
乙型肝炎病毒耐药及其防治;刘映霞;《中国感染控制杂志》;20070930;第6卷(第5期);第289-291页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103710466A (zh) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101701267B (zh) | 乙型肝炎病毒荧光定量pcr检测试剂盒及其应用 | |
CN102174660B (zh) | 乙型肝炎病毒荧光定量pcr检测试剂盒 | |
CN102154510B (zh) | 丙型肝炎病毒核酸定量检测试剂盒 | |
CN103060451B (zh) | 一种肺炎支原体mp检测试剂盒 | |
CN103060473B (zh) | 一种疱疹类病毒ebv检测试剂盒 | |
CN103725799B (zh) | 一种检测风疹病毒rna的方法及试剂盒 | |
CN103642941A (zh) | 一种乙型肝炎病毒(hbv)核酸定量检测试剂盒 | |
CN102146487B (zh) | 乙型肝炎病毒核酸定量检测试剂盒、检测方法、引物及其探针 | |
CN103740832B (zh) | 一种新型隐球菌检测试剂盒 | |
CN103710465B (zh) | 一种乙型肝炎病毒基因分型pcr检测试剂盒 | |
CN104846122A (zh) | 肠道病毒71型和柯萨奇病毒a16型核酸检测试剂盒(荧光pcr法) | |
CN105441589A (zh) | 人副流感病毒ⅰ、ⅱ、ⅲ、ⅳ型四重pcr检测试剂盒及其检测方法 | |
CN103710464B (zh) | 一种丙型肝炎病毒基因型检测试剂盒 | |
CN103710338A (zh) | 一种人类全血白细胞中dna提取试剂盒 | |
CN103122396B (zh) | 一种人巨细胞病毒hcmv检测试剂盒 | |
CN102586473A (zh) | 一种乙型肝炎病毒基因分型pcr检测试剂盒 | |
CN101550455A (zh) | 人副流感病毒分型及定量检测试剂盒 | |
CN103773897A (zh) | 一种用于丙型肝炎病毒核酸检测和基因分型的多重荧光pcr检测试剂盒及其应用 | |
CN103725800B (zh) | 一种人腺病毒检测试剂盒 | |
CN103710466B (zh) | 一种hbv的ymdd荧光pcr检测试剂盒 | |
CN114250325A (zh) | 快速检测乙型肝炎病毒9个基因型的引物、探针、试剂盒和方法 | |
CN100422344C (zh) | 乙型肝炎病毒基因分型的荧光pcr检测方法及其试剂盒 | |
CN105039599A (zh) | 分型定性检测乙型肝炎病毒的引物、探针及试剂盒 | |
CN102851394B (zh) | 一种检测肠道病毒71型rna的方法及试剂盒 | |
CN105420411A (zh) | 一种肠道病毒通用型、柯萨奇病毒a16型、肠道病毒71型核酸荧光pcr检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGWEIER MEDICAL INSPECTION CO., LTD. Free format text: FORMER OWNER: HUNAN SHENGXIANG BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20141119 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20141119 Address after: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Applicant after: Hunan company limited of Sheng Weier medical test institute Address before: 410012 No. 680, Lu Song Road, hi tech Industrial Development Zone, Hunan, Changsha Applicant before: Sansure Biotech Inc. |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Dai Lizhong Inventor after: Wu Kang Inventor after: Deng Zhongping Inventor before: Dai Lizhong Inventor before: Wu Kang Inventor before: Deng Zhongping Inventor before: Wang Jun |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: DAI LIZHONG WU KANG DENG ZHONGPING WANG JUN TO: DAI LIZHONG WU KANG DENG ZHONGPING |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGXIANG BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HUNAN SHENGWEIER MEDICAL INSPECTION CO., LTD. Effective date: 20150526 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150526 Address after: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee after: Sansure Biotech Inc. Address before: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Patentee before: Hunan company limited of Sheng Weier medical test institute |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: YMDD (Tyrosine-Methionine-aspartate-aspartate) fluorescence PCR (Polymerase Chain Reaction) detection kit for HBV (Hepatitis B Virus) Effective date of registration: 20170711 Granted publication date: 20150408 Pledgee: Ningbo free trade zone Terry with equity investment partnership (limited partnership)|Suzhou equity equity investment center (limited partnership)|Ningbo Meishan Bonded Port District, Jun and equity investment partnership (limited partnership)|Chen Bang Pledgor: Hunan Gene Technology Co.|Hunan San Xiang Biological Technology Co. Ltd. Registration number: 2017430000042 |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 410012 No. 680, Lu Song Road, hi tech Industrial Development Zone, Hunan, Changsha Patentee after: Shengxiang Biotechnology Co., Ltd Address before: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee before: Sansure Biotech Inc. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200217 Granted publication date: 20150408 Pledgee: Suzhou Lirui equity investment center (limited partnership)|Triton equity investment partnership (limited partnership)|JUNHE Tongrui equity investment partnership (limited partnership)|Chenbang Pledgor: SANSURE BIOTECH Inc. Registration number: 2017430000042 |